ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have earned an average rating of “Hold” from the five brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $28.25.

SPRY has been the subject of several research analyst reports. Leerink Partners set a $26.00 price objective on ARS Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Northland Securities initiated coverage on ARS Pharmaceuticals in a research report on Thursday. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, Zacks Research upgraded ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its position in ARS Pharmaceuticals by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after purchasing an additional 982 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in ARS Pharmaceuticals by 3.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company’s stock worth $596,000 after buying an additional 1,234 shares in the last quarter. ProShare Advisors LLC lifted its holdings in ARS Pharmaceuticals by 11.3% during the 4th quarter. ProShare Advisors LLC now owns 15,139 shares of the company’s stock worth $176,000 after buying an additional 1,532 shares in the last quarter. Belpointe Asset Management LLC lifted its holdings in ARS Pharmaceuticals by 8.9% during the 3rd quarter. Belpointe Asset Management LLC now owns 18,860 shares of the company’s stock worth $190,000 after buying an additional 1,537 shares in the last quarter. Finally, FAS Wealth Partners Inc. lifted its holdings in ARS Pharmaceuticals by 0.9% during the 4th quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company’s stock worth $2,358,000 after buying an additional 1,787 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Price Performance

NASDAQ SPRY traded down $0.05 during trading on Thursday, reaching $8.14. 241,960 shares of the company traded hands, compared to its average volume of 1,461,906. The company has a debt-to-equity ratio of 1.47, a quick ratio of 7.06 and a current ratio of 7.28. The stock’s 50 day moving average price is $8.90 and its two-hundred day moving average price is $9.63. The company has a market cap of $808.30 million, a price-to-earnings ratio of -4.67 and a beta of 0.86. ARS Pharmaceuticals has a 1-year low of $6.66 and a 1-year high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Monday, March 9th. The company reported ($0.42) EPS for the quarter, hitting the consensus estimate of ($0.42). The business had revenue of $28.09 million for the quarter, compared to the consensus estimate of $25.58 million. ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%. As a group, analysts anticipate that ARS Pharmaceuticals will post -0.55 EPS for the current year.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.